BrainAurora Medical Technology (HKG:6681) launched its HK$583.2 million initial public offering in Hong Kong on Monday.
The digital diagnostics and therapies provider is offering 181,112,000 shares at HK$3.22 apiece.
BrainAurora secured four cornerstone investors, including Tasly Pharmaceuticals (SHA:600535), which committed to subscribe to $48.5 million worth of IPO shares.
The issuer expects to disclose the allocations on Jan. 7. It will start trading on the Hong Kong bourse on Jan. 8, according to a Monday filing.
Deal proceeds will be used for research and development, clinical trials, technology upgrades, new cognitive centers, and working capital.
CICC, SPDB International, CMBC International, Fosun International, GF Securities, and several others are the joint book-runners of the IPO.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。